Budget Impact Analysis of High-Energy High-Protein (HEHP) Oral Nutritional Support (ONS) for the Treatment of Disease-Related Malnutrition (DRM) in Cancer Patients in the French Community Setting
Author(s)
Aditya Dular, MBA1, Valerie Carot, PhD2, Tini Nguyen, PharmD1, Matias Ricci, MBA3, David Alderson, MBA, MSc3, Thierry Tchoukouaha, MBA3.
1Nutricia Global, Hoofddorp, Netherlands, 2Nutricia Nutrition Clinique, Rueil-Malmaison, France, 3Cogentia Healthcare Consulting, Cambridge, United Kingdom.
1Nutricia Global, Hoofddorp, Netherlands, 2Nutricia Nutrition Clinique, Rueil-Malmaison, France, 3Cogentia Healthcare Consulting, Cambridge, United Kingdom.
OBJECTIVES: Demonstrate budget impact of different oral nutritional supplements (ONS) options for treating disease related malnutrition (DRM) in oncology patients in the community setting in France.
BACKGROUND: Up to 70% of oncological patients experience malnutrition. DRM is associated with reduced overall survival and increased risk of surgical complications. Even though, clinical guidelines recommend routine evaluation of nutritional status in cancer patients; multiple studies have reported that cancer patients do not receive adequate and timely nutrition support. ONS can be used to treat malnutrition. Two types of ONS are available, the standard ONS and the high-energy, high-protein (HEHP) ONS
METHODS: A systematic literature review (SLR) was performed alongside desk research to identify the burden of DRM and economic benefits of ONS in cancer patients. Included markets: EU4, UK & Netherlands. An indirect treatment comparison was performed comparing standard and HEHP-ONS, the results were integrated in a BI model developed from the perspective of the community-setting in France. The model compared three scenarios: no treatment, standard ONS and HEHP-ONS.
RESULTS: The SLR and desk research identified 6 key trials. The use of ONS was associated with a reduction in the incidence of hospital re-admission (26% no ONS; 12.7% standard ONS; and 11.5% for HEHP- ONS) and the hospital length of stay (LoS) (4 days no ONS, and 3 days for both standard and HEHP ONS) for each re-admission. The current use of HEHP ONS (60% of all ONS usage in community setting) in DRM cancer patients has led to a €6M savings versus Standard ONS. Increasing the use of HEHP-ONS to 80% market share in DRM cancer patients could generate an additional €1.8M savings in the French community setting.
CONCLUSIONS: The use of HEHP-ONS in the management of DRM in cancer patients could be associated with positive outcomes and cost savings for the French healthcare system.
BACKGROUND: Up to 70% of oncological patients experience malnutrition. DRM is associated with reduced overall survival and increased risk of surgical complications. Even though, clinical guidelines recommend routine evaluation of nutritional status in cancer patients; multiple studies have reported that cancer patients do not receive adequate and timely nutrition support. ONS can be used to treat malnutrition. Two types of ONS are available, the standard ONS and the high-energy, high-protein (HEHP) ONS
METHODS: A systematic literature review (SLR) was performed alongside desk research to identify the burden of DRM and economic benefits of ONS in cancer patients. Included markets: EU4, UK & Netherlands. An indirect treatment comparison was performed comparing standard and HEHP-ONS, the results were integrated in a BI model developed from the perspective of the community-setting in France. The model compared three scenarios: no treatment, standard ONS and HEHP-ONS.
RESULTS: The SLR and desk research identified 6 key trials. The use of ONS was associated with a reduction in the incidence of hospital re-admission (26% no ONS; 12.7% standard ONS; and 11.5% for HEHP- ONS) and the hospital length of stay (LoS) (4 days no ONS, and 3 days for both standard and HEHP ONS) for each re-admission. The current use of HEHP ONS (60% of all ONS usage in community setting) in DRM cancer patients has led to a €6M savings versus Standard ONS. Increasing the use of HEHP-ONS to 80% market share in DRM cancer patients could generate an additional €1.8M savings in the French community setting.
CONCLUSIONS: The use of HEHP-ONS in the management of DRM in cancer patients could be associated with positive outcomes and cost savings for the French healthcare system.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
EE86
Topic
Economic Evaluation, Health Policy & Regulatory
Topic Subcategory
Budget Impact Analysis
Disease
Nutrition, Oncology